Marksans Pharma soars on getting USFDA approval for Pregabalin Capsules
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Marksans Pharma is currently trading at Rs. 50.35, up by 1.10 points or 2.23% from its previous closing of Rs. 49.25 on the BSE.
The scrip opened at Rs. 49.75 and has touched a high and low of Rs. 51.55 and Rs. 49.75 respectively. So far 252631 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 88.00 on 22-Jul-2021 and a 52 week low of Rs. 38.70 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 51.55 and Rs. 48.30 respectively. The current market cap of the company is Rs. 2058.67 crore.
The promoters holding in the company stood at 48.25%, while Institutions and Non-Institutions held 4.98% and 46.77% respectively.
Marksans Pharma has received final approval from US Food & Drugs Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg.
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lyrica Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg, of Upjohn US 2 LLC.
Pregabalin capsules (RLD Lyrica) had estimated annual sales of $263 million in the U.S. (IQVIA MAT March 2022).
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.
.jpg)
